Previous close | 10.60 |
Open | 10.64 |
Bid | 10.58 x 1400 |
Ask | 10.64 x 1100 |
Day's range | 10.64 - 10.64 |
52-week range | 9.84 - 11.85 |
Volume | |
Avg. volume | 13,363 |
Market cap | 83.757M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 50.67 |
EPS (TTM) | 0.21 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
In this article, we discuss Farallon Capital: a global and diversified hedge fund and its top stock picks. If you want to skip our detailed analysis of these stocks, go directly to the Top 5 Stock Picks of Farallon Capital. Risk arbitrage or merger arbitrage is one of the most popular strategies that hedge funds […]
NEW YORK & VERO BEACH, Fla., August 11, 2023--HDL Therapeutics, Inc. ("HDL Therapeutics"), a privately held commercial stage biotech company with an FDA-approved cardiovascular therapy the Plasma Delipidation System (PDS-2™ System) for reducing coronary atheroma in patients with homozygous familial hypercholesterolemia (HoFH), has signed a definitive merger agreement with Swiftmerge Acquisition Corp. (NASDAQ: IVCP) ("Swiftmerge"), a special purpose acquisition company with a disruptive consumer
Key Insights Significantly high institutional ownership implies Swiftmerge Acquisition's stock price is sensitive to...